Nektar Therapeutics (NASDAQ:NKTR)‘s stock had its “buy” rating reiterated by equities researchers at Jefferies Group LLC in a research report issued on Friday. They presently have a $23.00 target price on the biopharmaceutical company’s stock. Jefferies Group LLC’s price target suggests a potential upside of 24.86% from the company’s current price.

NKTR has been the subject of several other research reports. Roth Capital set a $33.00 price objective on shares of Nektar Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 9th. Aegis reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Nektar Therapeutics in a report on Wednesday, May 10th. BidaskClub downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Evercore ISI began coverage on shares of Nektar Therapeutics in a report on Thursday. They issued an “in-line” rating and a $20.00 price objective for the company. Finally, William Blair reaffirmed an “outperform” rating on shares of Nektar Therapeutics in a report on Tuesday, July 18th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Nektar Therapeutics currently has an average rating of “Buy” and an average target price of $26.10.

Shares of Nektar Therapeutics (NASDAQ:NKTR) traded down 0.98% during trading on Friday, hitting $18.24. 527,999 shares of the stock were exchanged. The stock has a 50-day moving average of $20.53 and a 200 day moving average of $18.52. Nektar Therapeutics has a 12-month low of $11.41 and a 12-month high of $24.88. The stock’s market cap is $2.85 billion.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.04. The company had revenue of $34.60 million during the quarter, compared to analyst estimates of $33.64 million. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The business’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.36) EPS. Equities analysts predict that Nektar Therapeutics will post ($0.94) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Nektar Therapeutics (NKTR) Rating Reiterated by Jefferies Group LLC” was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/08/18/nektar-therapeutics-nktr-rating-reiterated-by-jefferies-group-llc.html.

In other Nektar Therapeutics news, SVP Ivan P. Gergel sold 8,389 shares of the business’s stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $21.04, for a total value of $176,504.56. Following the sale, the senior vice president now directly owns 51,961 shares in the company, valued at $1,093,259.44. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Roy A. Whitfield purchased 35,000 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was acquired at an average price of $17.95 per share, for a total transaction of $628,250.00. Following the completion of the transaction, the director now owns 133,000 shares of the company’s stock, valued at approximately $2,387,350. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 138,389 shares of company stock worth $2,908,403. 6.10% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of the company. Teachers Advisors LLC boosted its stake in shares of Nektar Therapeutics by 17.1% in the fourth quarter. Teachers Advisors LLC now owns 325,456 shares of the biopharmaceutical company’s stock valued at $3,993,000 after buying an additional 47,492 shares during the period. Bank of Montreal Can boosted its stake in shares of Nektar Therapeutics by 21.8% in the first quarter. Bank of Montreal Can now owns 8,195 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 1,464 shares during the period. Louisiana State Employees Retirement System boosted its stake in shares of Nektar Therapeutics by 2.1% in the first quarter. Louisiana State Employees Retirement System now owns 62,700 shares of the biopharmaceutical company’s stock valued at $1,472,000 after buying an additional 1,300 shares during the period. Everence Capital Management Inc. acquired a new stake in shares of Nektar Therapeutics during the first quarter valued at approximately $238,000. Finally, State of Alaska Department of Revenue boosted its stake in shares of Nektar Therapeutics by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 17,050 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 460 shares during the period. Hedge funds and other institutional investors own 93.02% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.